Top

Published in:

01-07-2018 | Original Article

Clinical value of systemic symptoms in IgA nephropathy with ANCA positivity

Authors: Lijiao Xie, Jianghua He, Xing Liu, Sha Tang, Weili Wang, Furong Li, Ying Zhang, Jun Zhang, Yunjian Huang, Jinghong Zhao, Yafei Li, Jingbo Zhang

Published in: Clinical Rheumatology | Issue 7/2018

Abstract

Our aim was to evaluate the pathogenic role of anti-neutrophil cytoplasmic antibodies (ANCAs) in patients with IgA nephropathy (IgAN). A total of 2390 patients with biopsy-confirmed IgAN were analyzed retrospectively. Thirty-five IgAN patients with ANCA and 40 IgAN patients without ANCA were enrolled. According to the Birmingham Vasculitis Activity Score (BVAS) items, the ANCA-positive patients were further divided into two subgroups which with or without systemic symptoms. The cumulative renal survival rate was calculated using Kaplan–Meier analysis. Comparisons between groups were made using the log rank test. Among the 35 ANCA-positive patients, 14 (40%) had systemic symptoms. Compared with ANCA-positive patients without systemic symptoms, ANCA-positive patients with systemic symptoms had a shorter duration of disease (1.0 [IQR, 0.3–6.8] vs. 6.0 [IQR, 2.0–21.0], P = 0.011); showed worse renal function with lower levels of eGFR (24.2 [IQR, 11.7–74.9] vs. 100.1 [IQR, 59.6–130.2] mL/min/1.73 m², P = 0.002), serum albumin (30.4 [IQR, 27.4–34.8] vs. 41.5 [IQR, 35.1–44.4] g/L, P = 0.001), and hemoglobin (96.1 ± 21.5 vs. 118.2 ± 22.4 g/L, P = 0.006); and presented relatively higher incidences of rapidly deteriorating kidney function (28.6 vs. 0.0%, P = 0.039) and moderate-to-severe tubular atrophy (78.6 vs. 23.8%, P = 0.001). Kaplan–Meier analysis had shown that ANCA-positive patients with systemic symptoms had lower cumulative renal survival rate compared with both ANCA-positive patients without systemic symptoms and ANCA-negative patients (log rank = 14.40, P < 0.001). Evaluation of systemic symptoms is a simple, readily available clinical tool to predictive the pathogenic role of ANCA in IgAN.

Falk RJ, Terrell RS, Charles LA, Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87(11):4115–4119. https://doi.org/10.1073/pnas.87.11.4115 CrossRefPubMedPubMedCentral

Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110(7):955–963. https://doi.org/10.1172/JCI0215918 CrossRefPubMedPubMedCentral

Bansal PJ, Tobin MC (2004) Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93(4):398–401. https://doi.org/10.1016/S1081-1206(10)61400-7 CrossRefPubMed

Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage COS, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RAF, Pusey CD, on behalf of the European Vasculitis Study Group (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180–2188. https://doi.org/10.1681/ASN.2007010090 CrossRefPubMed

Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor JA, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ (2013) Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 123(4):1773–1783. https://doi.org/10.1172/JCI65292 CrossRefPubMedPubMedCentral

Radice A, Sinico RA (2005) Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 38(1):93–103. https://doi.org/10.1080/08916930400022673 CrossRefPubMed

Anaele CU, Srisung W, Tomacruz Y, Laski M (2015) Antineutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis associated with multiple myeloma. Case Rep Nephrol Dial 5(2):124–129. https://doi.org/10.1159/000432394 CrossRefPubMedPubMedCentral

Tanemoto M, Miyakawa H, Hanai J, Yago M, Kitaoka M, Uchida S (1995) Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves’ disease: report of three adult cases. Am J Kidney Dis 26(5):774–780. https://doi.org/10.1016/0272-6386(95)90441-7 CrossRefPubMed

Hervier B, Hamidou M, Haroche J, Durant C, Mathian A, Amoura Z (2012) Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int 32(10):3285–3290. https://doi.org/10.1007/s00296-011-2055-z CrossRefPubMed

10.

Lindic J, Vizjak A, Ferluga D, Kovac D, Ales A, Kveder R et al (2009) Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. Ther Apher Dial 13(4):278–281. https://doi.org/10.1111/j.1744-9987.2009.00724.x CrossRefPubMed

11.

Boulis E, Majithia V, McMurray R (2013) Adult-onset Henoch–Schonlein purpura with positive c-ANCA (anti-proteinase 3): case report and review of literature. Rheumatol Int 33(2):493–496. https://doi.org/10.1007/s00296-010-1608-x CrossRefPubMed

12.

Yang YZ, Shi SF, Chen YQ, Chen M, Yang YH, Xie XF et al (2015) Clinical features of IgA nephropathy with serum ANCA positivity: a retrospective case-control study. Clin Kidney J 8(5):482–488. https://doi.org/10.1093/ckj/sfv078 CrossRefPubMedPubMedCentral

13.

Ramirez SB, Rosen S, Niles J, Somers MJ (1998) IgG antineutrophil cytoplasmic antibodies in IgA nephropathy: a clinical variant? Am J Kidney Dis 31(2):341–344. https://doi.org/10.1053/ajkd.1998.v31.pm9469508 CrossRefPubMed

14.

Kucuk A, Solak Y, Gaipov A, Bagcaci S, Esen H, Turk S, Tunc R (2016) Co-existing proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis with immunoglobulin A nephropathy. Korean J Intern Med 31(1):194–196. https://doi.org/10.3904/kjim.2016.31.1.194 CrossRefPubMed

15.

Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, Ivens K, Heering PJ (2010) Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis 55(2):259–268. https://doi.org/10.1053/j.ajkd.2009.09.031 CrossRefPubMed

16.

Houben E, Bax WA, van Dam B, Slieker WA, Verhave G, Frerichs FC et al (2016) Diagnosing ANCA-associated vasculitis in ANCA positive patients: a retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine 95(40):e5096. https://doi.org/10.1097/MD.0000000000005096 CrossRefPubMedPubMedCentral

17.

Winters MJ, Hurley RM, Lirenman DS (2002) ANCA-positive glomerulonephritis and IgA nephropathy in a patient on propylthiouracil. Pediatr Nephrol 17(4):257–260. https://doi.org/10.1007/s00467-001-0807-9 CrossRefPubMed

18.

Haas M, Jafri J, Bartosh SM, Karp SL, Adler SG, Meehan SM (2000) ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis 36(4):709–718. https://doi.org/10.1053/ajkd.2000.17615 CrossRefPubMed

19.

Ogawa N, Yano S, Yamane Y, Nishiki M, Yamaguchi T, Tsukamoto T, Muso E, Sugimoto T (2007) MPO-ANCA-positive IgA nephropathy successfully treated with tonsillectomy. Clin Exp Nephrol 11(4):326–331. https://doi.org/10.1007/s10157-007-0506-3 CrossRefPubMed

20.

Barcelos FL, Fontes TM (2015) Case report-IgA nephropathy ANCA positive with favorable outcome. J Bras Nefrol 37:414–417, 3, DOI: https://doi.org/10.5935/0101-2800.20150063

21.

Fabiano RC, Pinheiro SV, Simões E, Silva AC (2016) Immunoglobulin A nephropathy: a pathophysiology view. Inflamm Res 65(10):757–770. https://doi.org/10.1007/s00011-016-0962-x CrossRefPubMed

22.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227. https://doi.org/10.1136/ard.2006.054593 CrossRefPubMed

23.

Land J, Rutgers A, Kallenberg CG (2014) Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. Nephrol Dial Transplant 29(4):739–745. https://doi.org/10.1093/ndt/gft416 CrossRefPubMed

24.

Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66(3):283–292. https://doi.org/10.1136/ard.2005.051078 PubMedCrossRef

25.

Roberts I, Cook T, Troyanov S, Alpers C, Amore A, Barratt J et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546–556. https://doi.org/10.1038/ki.2009.168 CrossRefPubMed

26.

Davin JC, Ten Berge IJ, Weening JJ (2001) What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int 59(3):823–834. https://doi.org/10.1046/j.1523-1755.2001.059003823.x CrossRefPubMed

27.

Kong XL, Ma YC, Chen JH, Luo Q, XQ Y, Li Y et al (2013) Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant 28(3):641–651. https://doi.org/10.1093/ndt/gfs491 CrossRefPubMed

28.

Bhowmik D, Sinha S, Gupt A, Tiwari SC, Agarwal SK (2011) Clinical approach to rapidly progressive renal failure. J Assoc Physicians India 59:38–41PubMed

29.

Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S (2014) Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 18(3):481–486. https://doi.org/10.1007/s10157-013-0849-x CrossRefPubMed

30.

Luqmani RA (1994) Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med 87:671–678

31.

Pu L, Li GS, Zou YR, Zhang P, Wang L (2017) Clinical predictors of outcome in patients with anti-neutrophil cytoplasmic autoantibody-related renal vasculitis: experiences from a single-center. Chin Med J 130:899–905, 8, DOI: https://doi.org/10.4103/0366-6999.204099

32.

YJ O, Ahn SS, Park ES, Jung SM, Song JJ, Park YB et al (2017) Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa. Rheumatol Int 37:685–694CrossRef

33.

Wallace ZS, Miloslavsky EM, Cascino M, Unizony SH, Lu N, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera R, St.Clair EW, Specks U, Brunetta P, Choi HK, Stone JH (2017) Effect of disease activity, glucocorticoid exposure, and rituximab on body composition during induction treatment of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res 69(7):1004–1010. https://doi.org/10.1002/acr.23099 CrossRef

34.

Haris Á, Polner K, Arányi J, Braunitzer H, Kaszás I, Rosivall L, Kökény G, Mucsi I (2017) Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis. BMC Nephrol 18:76, 1, DOI: https://doi.org/10.1186/s12882-017-0491-z

35.

Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27(4):1479–1485. https://doi.org/10.1093/ndt/gfr527 CrossRefPubMed

36.

Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, Itabashi M, Takei T, Uchida K, Nitta K (2014) Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 9(3):e91756. https://doi.org/10.1371/journal.pone.0091756 CrossRefPubMedPubMedCentral

37.

Cattran D, Coppo R, Cook T, Feehally J, Roberts I, Troyanov S et al (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5):534–545. https://doi.org/10.1038/ki.2009.243 CrossRefPubMed

38.

Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L, on behalf of the European Vasculitis Study (EUVAS) Group (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043, 6, DOI: https://doi.org/10.1136/ard.2009.109389

39.

Huang X, Wang Y, Xie LJ, Zhang Y, Tang S, Yin SW et al (2015) IgA nephropathy with anti-neutrophil cytoplasmic antibody seropositivity. Clin Nephrol 84(3):156–164. https://doi.org/10.5414/CN108571 CrossRefPubMed

40.

Bhamra K, Luqmani R (2012) Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep 14(6):494–500. https://doi.org/10.1007/s11926-012-0291-1 CrossRefPubMed

41.

Küçük H, Göker B, Varan Ö, Dumludag B, Haznedaroğlu Ş, Öztürk MA, Tufan A, Emiroglu T, Erten Y (2017) Predictive value of neutrophil/lymphocyte ratio in renal prognosis of patients with granulomatosis with polyangiitis. Ren Fail 39(1):273–276. https://doi.org/10.1080/0886022X.2016.1259633 CrossRefPubMed

Title: Clinical value of systemic symptoms in IgA nephropathy with ANCA positivity
Authors: Lijiao Xie
Jianghua He
Xing Liu
Sha Tang
Weili Wang
Furong Li
Ying Zhang
Jun Zhang
Yunjian Huang
Jinghong Zhao
Yafei Li
Jingbo Zhang
Publication date: 01-07-2018
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 7/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3931-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical value of systemic symptoms in IgA nephropathy with ANCA positivity

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2018

Decreased IgG4 ACPA levels in responders and increased CD1c+ classical dendritic cells in non-responders of patients with rheumatoid arthritis under therapy

Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis

Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis

Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein

Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial

Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page